SAR113244 Biosimilar – Anti-CXC-R5 mAb – Research Grade from ProteoGenix; catalogue PX-TA1915; research use only.
Know who made it. See the evidence. Buy through one marketplace.
SAR113244 Biosimilar – Anti-CXC-R5 mAb is a monoclonal antibody (mAb) that has been developed as a biosimilar to the original anti-CXC-R5 mAb. This biosimilar has been designed to have a similar structure, activity and application as the original mAb, making it a promising therapeutic option for various diseases.
SAR113244 Biosimilar – Anti-CXC-R5 mAb is a monoclonal antibody that specifically targets the CXC-R5 receptor. It is a recombinant humanized IgG1 antibody, meaning that it is derived from human antibody sequences but has been modified to reduce immunogenicity. The antibody has a molecular weight of approximately 150 kDa and consists of two heavy chains and two light chains, connected by disulfide bonds. The variable region of the antibody is responsible for binding to the CXC-R5 receptor, while the constant region determines the effector functions of the antibody.
The main activity of SAR113244 Biosimilar – Anti-CXC-R5 mAb is its ability to bind to the CXC-R5 receptor with high affinity and specificity. The CXC-R5 receptor is a chemokine receptor that is expressed on the surface of various cells, including immune cells. It plays a crucial role in inflammatory responses, cell migration and proliferation. By binding to the CXC-R5 receptor, SAR113244 Biosimilar – Anti-CXC-R5 mAb can block the binding of its natural ligands, such as chemokines, and inhibit the downstream signaling pathways. This leads to a reduction in inflammation and immune cell recruitment, making it a potential therapeutic target for various diseases.
SAR113244 Biosimilar – Anti-CXC-R5 mAb has shown promising results in preclinical studies as a potential treatment for various diseases. Its main application is in the treatment of inflammatory and autoimmune diseases, such as rheumatoid arthritis, multiple sclerosis, and psoriasis. By targeting the CXC-R5 receptor, the antibody can modulate the immune response and reduce inflammation, providing relief to patients suffering from these conditions.
In addition, SAR113244 Biosimilar – Anti-CXC-R5 mAb has also shown potential in the treatment of certain types of cancer. The CXC-R5 receptor is overexpressed on the surface of some cancer cells, and its activation has been linked to tumor growth and metastasis. By blocking the CXC-R5 receptor, SAR113244 Biosimilar – Anti-CXC-R5 mAb can inhibit tumor growth and prevent the spread of cancer cells.
SAR113244 Biosimilar – Anti-CXC-R5 mAb is currently in the research grade stage, meaning that it is still undergoing preclinical and clinical studies. These studies are necessary to evaluate the safety, efficacy and pharmacokinetics of the antibody before it can be approved for clinical use. The research grade of SAR113244 Biosimilar – Anti-CXC-R5 mAb also allows for further optimization and refinement of the antibody to improve its therapeutic potential.
SAR113244 Biosimilar – Anti-CXC-R5 mAb is a promising biosimilar that has been developed to target the CXC-R5 receptor. Its structure, activity and application make it a potential therapeutic option for inflammatory and autoimmune diseases, as well as certain types of cancer. As it continues to undergo research and development, SAR113244 Biosimilar – Anti-CXC-R5 mAb has the potential to provide relief to patients suffering from these diseases.
ProteoGenix catalogue number PX-TA1915. For research use only.
Target: SAR113244 Biosimilar – Anti-CXC-R5 mAb – Research Grade; Clonality: Monoclonal Antibody; Expression system: XtenCHO; Buffer: PBS buffer PH7.5; Applications: ELISA, WB.
Available configurations: 50ug, 100ug, 1mg.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Target | WB | IHC-P | IHC-Fr | IF/ICC | Flow Cyt | IP | ChIP | ELISA |
|---|---|---|---|---|---|---|---|---|
| SAR113244 Biosimilar – Anti-CXC-R5 mAb – Research Grade |
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
